ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
MENLO PARK, CalifChem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.
Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Related Content
